What caused the significant drop in net income compared to the previous year?

The primary reason for the decrease in net income was the recognition of $353.9 million in asset impairments, restructuring, and other special charges during the first quarter of 2003. These charges were related to streamlining operations, impairments of manufacturing assets, and an impairment of the company's investment in Isis Pharmaceuticals.

How did key products perform during the quarter?

Several key products showed strong sales growth. Zyprexa's worldwide sales increased by 17% to $958.3 million. Diabetes care products (Humalog, Humulin, Actos) saw a 26% rise in worldwide revenues. Gemzar and Evista also performed well with 18% and 20% increases respectively. Additionally, the new ADHD drug Strattera launched in the quarter and generated $55.0 million in sales, exceeding initial expectations.

What is the company's outlook for the remainder of 2003?

Eli Lilly expects earnings per share for the full year 2003 to be between $2.27 and $2.37, excluding future unusual items. For the second quarter of 2003, excluding unusual items, EPS is projected to be between $0.59 and $0.61. The company anticipates that cash generated from operations, along with existing cash reserves, will be sufficient to fund its operating needs, debt service, capital expenditures, share repurchases, and dividends for the remainder of the year.

Are there any significant legal or regulatory risks highlighted in the report?

Yes, the company is involved in ongoing patent litigations concerning potential generic versions of Zyprexa and Evista, with trials scheduled in 2004 and 2005, respectively. An unfavorable outcome in these cases could materially impact financial results. Additionally, the company is addressing observations from FDA inspections regarding cGMP regulations at its manufacturing facilities, with ongoing discussions and planned reinspections. While the company believes its environmental and litigation accruals are adequate, these matters could potentially be material to the results of operations in any one accounting period.

LLY 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company reported a net income of $407.0 million, or $0.38 per diluted share, for the first quarter of 2003. This represents a decrease from the $629.2 million, or $0.58 per diluted share, reported in the same period of the prior year. The decline in profitability was primarily attributed to significant asset impairments, restructuring, and other special charges totaling $353.9 million incurred during the quarter, notably related to manufacturing assets and an investment in Isis Pharmaceuticals. Despite these charges, the company saw a 13% increase in net sales, reaching $2.89 billion, driven by strong performances from key products such as Zyprexa, Humalog, Actos, Gemzar, and Evista, along with the launch of Strattera.

Key Highlights

1Net sales increased by 13% to $2.89 billion, indicating robust top-line growth, with international sales up 15%.
2Significant 'asset impairments, restructuring, and other special charges' of $353.9 million negatively impacted net income, resulting in a 35% decrease year-over-year.
3Zyprexa demonstrated strong performance with a 17% increase in worldwide sales to $958.3 million.
4Diabetes care products, including Humalog and Actos, showed substantial growth with a 26% increase in worldwide revenues.
5Strattera, a new ADHD treatment, generated $55.0 million in initial sales, exceeding expectations.
6The company's effective tax rate decreased to 17.6% from 22.0% in the prior year's quarter.
7Cash, cash equivalents, and short-term investments remained strong at $3.55 billion, with substantial cash flow from operations ($589.0 million).

ELI LILLY & Co Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions